Connect with us
  • Elysium


ONWARD spinal stimulation tech awarded new patents

The pioneering business moves further towards its goal of bringing its ARC spinal cord therapy to reality



The development of ONWARD spinal stimulation therapy continues to move towards commercialisation with the business being awarded nine new patents for its pioneering technology. 

ONWARD now has over 310 issued or pending patents covering its therapies to restore movement, independence and health in people living with spinal cord injury. 

Seven of its new patents are in collaboration with leading neuroscience research laboratories at Caltech, UCLA, EPFL and University of Louisville.

It marks the latest step in ONWARD’s journey towards its ARC technology becoming commercial reality, with ambitions for it to be introduced as early as next year. 

“Our many exclusive IP license agreements with the world’s top neuroscience research universities continue to bear fruit, adding to an already impressive IP portfolio of over 300 issued or pending patents,” said Dave Marver, CEO of ONWARD. 

“We are taking full advantage of our first-mover position to secure seminal and strategic intellectual property borne from our own engineering labs or prosecuted in collaboration with others.”

The patents cover a broad range of technologies and activities encompassing ONWARD’s implantable and external technology platforms, ARC IM and ARC EX, and protect key elements of those systems such as lead designs, spinal cord stimulation paradigms, closed-loop control systems and machine learning algorithms. 

The further development of the ARC technology towards commercialisation comes as its Up-LIFT pivotal trial progresses, with 65 people globally now trialling its pioneering stimulation therapy. 

One site, the NHS Greater Glasgow and Clyde (NHSGGC), has already reported significant initial positives from its trial, with some participants regaining movement in their arms and toes. 

ONWARD expects to initially commercialise its technology in the US, Germany, France, UK, Switzerland and the Netherlands.


Sign up for the NR Times newsletter
I would like to receive by email other offers, promotions and services from Aspect Publishing Ltd and its group companies.*